SOURCE Shire plc
European stocks rebounded Friday as investors shook off the pessimism of recent days, with price action supported by both M&A as well as corporate earnings news.
Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.
Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home
Shire plc SHP shares shot to the top of the FTSE 100 Tuesday after the drugmaker beat expectations for earnings in the first-quarter and reiterated its full-year guidance.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.